Assessing Curaleaf Holdings (TSX:CURA) Valuation After Recent Share Price Weakness

Simply Wall St

Tue, February 17, 2026 at 9:22 AM GMT+9 2 min read

In this article:

CURLF

+1.68%

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.

Curaleaf Holdings stock: event-driven snapshot

Curaleaf Holdings (TSX:CURA) has been drawing attention after recent share price moves, with the stock showing a mix of shorter term pressure and stronger past 3 months and 1 year performance data.

See our latest analysis for Curaleaf Holdings.

At the latest share price of CA$3.31, Curaleaf’s shorter term share price returns have been weak, including a 1 month share price return of a 10.30% decline, while its 1 year total shareholder return of 59.90% shows stronger momentum over a longer horizon.

If Curaleaf’s recent swings have you thinking about where else growth stories might emerge, this could be a good moment to widen your search with our 3 top founder-led companies.

With Curaleaf reporting CA$1,275.825m in revenue, a CA$277.169m loss, and the share price around CA$3.31, is the current valuation leaving upside on the table, or is the market already pricing in future growth?

Most Popular Narrative: 33% Undervalued

Curaleaf’s most followed narrative sets a fair value of CA$4.94 against the latest CA$3.31 share price, framing a wide gap that hinges on future execution.

Rapid expansion and regulatory breakthroughs in international markets, notably the strong sequential and yearly growth in Germany, new entry into Turkey (an 87-million-person underpenetrated market), and advancements such as the first medically certified EU device, meaningfully increase Curaleaf’s total addressable market, diversify revenue streams beyond the saturated U.S. market, and are likely to drive sustained long-term revenue growth.

Read the complete narrative.

Curious what kind of revenue mix, margin lift, and future earnings multiple are baked into that valuation story? The full narrative spells out the assumptions and the leap in profitability needed to get there.

Result: Fair Value of CA$4.94 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, this depends on pricing pressure easing and new international markets, such as Turkey and Australia, scaling as planned. Both of these factors could easily disappoint.

Find out about the key risks to this Curaleaf Holdings narrative.

Build Your Own Curaleaf Holdings Narrative

If you look at the numbers and come to a different conclusion, or just prefer to test your own assumptions, you can build a complete thesis using our Do it your way tool in just a few minutes.

A great starting point for your Curaleaf Holdings research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.

Story continues  

Ready for more investment ideas?

If Curaleaf has sharpened your thinking, do not stop here, the Simply Wall St Screener can surface other opportunities you might regret overlooking later.

Zero in on quality at a discount by scanning our 5 high quality undervalued stocks which blend solid fundamentals with prices that may not fully reflect them yet.

Steady your portfolio with income ideas using our 7 dividend fortresses focused on companies offering yields from stronger dividend profiles.

Protect your downside first by checking our 7 resilient stocks with low risk scores which highlight businesses with lower overall risk scores.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include CURA.TO.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info